Processing

Please wait...

Settings

Settings

Goto Application

1. ES2907467 - Fragmentos variables insertables de anticuerpos y dominios a1-a2 modificados de ligandos NKG2D

Office
Spain
Application Number 15864650
Application Date 04.12.2015
Publication Number 2907467
Publication Date 25.04.2022
Publication Kind T3
IPC
C07H 21/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
02with ribosyl as saccharide radical
C07H 21/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
04with deoxyribosyl as saccharide radical
C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
C07K 14/74
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
74Major histocompatibility complex (MHC)
C07K 14/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
CPC
C07K 16/2818
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
2818against CD28 or CD152
C07K 16/2851
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2851against the lectin superfamily, e.g. CD23, CD72
C07K 16/2863
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2863against receptors for growth factors, growth regulators
C07K 2317/31
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
31multispecific
C07K 2317/622
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
60characterized by non-natural combinations of immunoglobulin fragments
62comprising only variable region components
622Single chain antibody (scFv)
C07K 2317/73
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Applicants Xyphos Biosciences Inc.
Inventors LANDGRAF, Kyle
STEIGER, Daniel
WILLIAMS, Steven R.
MARTIN, David W.
Agents Pons Ariño Angel
Priority Data 201462088456 P 05.12.2014 US
Title
(ES) Fragmentos variables insertables de anticuerpos y dominios a1-a2 modificados de ligandos NKG2D
Abstract
(ES) Una molécula de dominio α1-α2 que comprende una secuencia de aminoácidos que tiene al menos un 80 % de identidad con SEQ ID NO: 17, en donde dicha molécula de dominio contiene todos de (a)-(c): (a) un resto S en la posición correspondiente a la posición 103 de SEQ ID NO: 17, (b) un resto A, P, S, T o H en la posición correspondiente a la posición 165 de SEQ ID NO: 17; y (c) un resto G en la posición correspondiente a la posición 162 de SEQ ID NO: 17, y en donde dicha molécula de dominio muestra una mayor afinidad de unión a un NKG2D humano en comparación con SEQ ID NO: 17.